IQVIA (NYSE:IQV) Upgraded by Wall Street Zen to Buy Rating

IQVIA (NYSE:IQV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Friday.

Several other brokerages have also weighed in on IQV. Stifel Nicolaus increased their price objective on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup boosted their price target on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research report on Wednesday, October 29th. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on shares of IQVIA in a report on Wednesday, September 3rd. Finally, Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $240.61.

IQVIA Trading Down 1.8%

IQVIA stock opened at $227.63 on Friday. The stock has a 50-day moving average price of $210.07 and a 200 day moving average price of $183.55. IQVIA has a 52 week low of $134.65 and a 52 week high of $234.29. The stock has a market cap of $38.77 billion, a PE ratio of 31.23, a P/E/G ratio of 2.60 and a beta of 1.34. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently bought and sold shares of the company. Boston Partners bought a new position in IQVIA during the third quarter worth $676,698,000. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $515,772,000. Norges Bank acquired a new stake in IQVIA in the second quarter worth $270,160,000. AQR Capital Management LLC boosted its holdings in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.